ClinicalTrials.gg
CompletedNCT03860935ATTRibute-CMUpdated Jun 27, 2024Results posted

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

A Phase 3 interventional study of acoramidis and Placebo Oral Tablet in Amyloidosis, Amyloid Cardiomyopathy and Transthyretin Amyloidosis, sponsored by Eidos Therapeutics, a BridgeBio company. Completed at 104 sites in 18 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-06-27.

Primary conditionAmyloidosis, Hereditary, Transthyretin-RelatedRegistry: AmyloidosisReclassifiedWhy we changed it
Registry
Amyloidosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Amyloidosis, Hereditary, Transthyretin-Related
Why
  1. The study's listed conditions name Amyloidosis, Hereditary, Transthyretin-Related, a narrower term within Amyloidosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eidos Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
632
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States — 10 open to participants now, 12 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · United States.

Enrollment
4th of 23
632 · median 150
Started
2019
with 6 others
Phase 3
10 of 37
3 open now
Registered
9th of 37
by date
Lead sponsor
4 of 37
Eidos Therapeutics, a BridgeBio company

Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, this one is the 4th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2019, is one of 10 in phase 3, and was the 9th registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

10 of the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, or all of them as a file.
02

Study summary

Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Read the detailed description

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed condition believed to affect more than 400,000 people worldwide. In ATTR-CM, the accumulation of transthyretin (TTR) amyloid results in thickening and stiffening of the heart, which often leads to heart failure or even death.

There are two forms of ATTR-CM:

  • Wild Type* This form of the condition primarily develops in older individuals who do not carry gene mutations.
  • Hereditary* This form of the condition comes from gene mutations passed down in families.

In this study we are researching the investigational drug acoramidis HCl 800 mg administered orally twice a day. Through the study, we want to evaluate the efficacy and safety of acoramidis in patients with ATTR-CM versus placebo.

This is a 30 month, randomized, double-blind, placebo-controlled study. This means that, during the 30 month study, investigators conducting the research and study participants will not know whether the study participant is receiving acoramidis or placebo.

The primary outcomes of the study are:

  1. The impact of acoramidis versus placebo on the change in distance walked on the 6 minute walk test (6MWT) after 12 months of treatment compared to baseline.
  2. The impact of acoramidis versus placebo on the hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP, and change in from baseline in 6MWT over a 30-month fixed treatment duration.

At the end of 30 months, participants may be eligible to receive investigational acoramidis, and there is no placebo. This is called an "open label extension." This separate study may help us better understand the safety related to taking acoramidis over a longer period of time.

03

Conditions studied

  • Amyloidosis
  • Amyloid Cardiomyopathy
  • Transthyretin Amyloidosis
  • Cardiomyopathies
  • Heart Diseases

Keywords

  • Amyloidosis
  • ATTR-CM
  • Transthyretin
  • Amyloid
  • TTR
04

In context

Amyloidosis, Hereditary, Transthyretin-Related Reclassified

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

This study's enrollment of 632 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Lead sponsor

Eidos Therapeutics, a BridgeBio company is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

First submitted after Eidos Therapeutics became part of BridgeBio.

Compared within Amyloidosis, Hereditary, Transthyretin-Related, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Amyloidosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an established diagnosis of ATTR-CM with either wild-type TTR or variant TTR genotype
  • Have a history of heart failure evidenced by at least one prior hospitalization for heart failure or clinical evidence of heart failure without prior heart failure hospitalization manifested by signs or symptoms of volume overload or elevated intracardiac pressures or heart failure symptoms that required or require ongoing treatment with a diuretic.
  • (NYHA) Class I-III symptoms due to ATTR cardiomyopathy.
  • On stable doses of cardiovascular medical therapy
  • Completed ≥150 m on the 6MWT on 2 tests that are within 15% of total distance walked prior to randomization
  • Biomarkers of myocardial wall stress, NT-proBNP level ≥300 pg/mL at screening
  • Have left ventricular wall (interventricular septum or left ventricular posterior wall) thickness ≥12 mm

Exclusion criteria

Exclusion Criteria:

  • Had acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or within 90 days prior to screening
  • Has hemodynamic instability
  • Likely to undergo heart transplantation within a year of screening
  • Confirmed diagnosis of primary (light chain) amyloidosis
  • Biomarkers of myocardial wall stress, NT-proBNP level ≥8500 pg/mL at screening
  • Measure of kidney function, by MDRD formula \<15 mL/min/1.73 m2
  • Current treatment with marketed drug products and other agents for the treatment of ATTR-CM
  • Current treatment with calcium channel blockers with conduction system effects (e.g. verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed. The use of digitalis will only be allowed if required for management of atrial fibrillation with rapid ventricular response
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
632 participants (actual)

Study arms

  • Experimental
    acoramidis HCl 800 mg

    Subjects will receive acoramidis HCl 800 mg twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.

    Drug: acoramidis

  • Placebo comparator
    Placebo

    Subjects will receive placebo to match twice daily. 6MWT primary outcome will be assessed at the end of 12 months. The hierarchical combination of All-Cause mortality, cumulative frequency of cardiovascular-related hospitalizations, change from baseline in NT-proBNP levels, and change from baseline in distance walked on the 6MWT will be assessed after 30 months of treatment.

    Drug: Placebo Oral Tablet

Interventions

  • TTR stabilizer administered orally twice daily (BID)

    Also known as: AG10, ALXN2060

  • DrugPlacebo Oral Tablet

    Non-active control administered orally twice daily (BID)

07

What researchers measure

Primary outcomes

  1. A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.

    The endpoint was analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality, cumulative frequency of CV-related hospitalizations, change from baseline in NT-proBNP and change from baseline in 6MWT in a hierarchical fashion. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who had heart transplantation or implantation of a cardiac mechanical assist device were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.

    Time frame: Baseline up to Month 30

Secondary outcomes

  1. Change From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT)

    6MWT measures the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.

    Time frame: Month 30

  2. Change From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)

    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). The summary score of Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores) was calculated. Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.

    Time frame: Month 30

  3. Change From Baseline to Month 30 in Serum TTR (Prealbumin) Level

    Serum TTR (Prealbumin) is an in vivo biomarker of stabilization.

    Time frame: Month 30

  4. All-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD)

    Number of deaths due to any cause was analyzed. Participants who had heart transplantation or implantation of a CMAD were handled in the same manner as death.

    Time frame: Baseline up to Month 30

08

Results

Posted Jun 27, 2024

Participant flow

Participant flow — Overall Study
MilestoneAcoramidis HCl 800 mgPlacebo
Started421211
Completed331154
Not completed9057
Withdrew: Withdrawal of consent156
Withdrew: Death7551

Outcome measures

PrimaryA Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.

The endpoint was analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality, cumulative frequency of CV-related hospitalizations, change from baseline in NT-proBNP and change from baseline in 6MWT in a hierarchical fashion. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who had heart transplantation or implantation of a cardiac mechanical assist device were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.

Time frame:
Baseline up to Month 30
Reported as:
Number · Percent of Wins from Win Ratio
A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.
Percent of Wins from Win RatioAcoramidis HCl 800 mgPlacebo
A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.63.735.9
Statistical analysis
  • Acoramidis HCl 800 mg vs Placebo · Finkelstein-Schoenfeld Method · p = <0.0001
SecondaryChange From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT)

6MWT measures the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.

Time frame:
Month 30
Reported as:
Least squares mean · Meter
Change From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT)
MeterAcoramidis HCl 800 mgPlacebo
Change From Baseline to Month 30 in the Distance Walked During the 6 Minute Walk Test (6MWT)-64.65 ± 5.508-104.29 ± 7.772
Statistical analysis
  • Acoramidis HCl 800 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 39.64 · 96% CI 20.18 to 59.10
SecondaryChange From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)

KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). The summary score of Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores) was calculated. Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.

Time frame:
Month 30
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
Score on a scaleAcoramidis HCl 800 mgPlacebo
Change From Baseline to Month 30 of the Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)-11.48 ± 1.181-21.42 ± 1.651
Statistical analysis
  • Acoramidis HCl 800 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 9.94 · 96% CI 5.79 to 14.10
SecondaryChange From Baseline to Month 30 in Serum TTR (Prealbumin) Level

Serum TTR (Prealbumin) is an in vivo biomarker of stabilization.

Time frame:
Month 30
Reported as:
Least squares mean · mg/dL
Change From Baseline to Month 30 in Serum TTR (Prealbumin) Level
mg/dLAcoramidis HCl 800 mgPlacebo
Change From Baseline to Month 30 in Serum TTR (Prealbumin) Level5.78 ± 0.391-1.32 ± 0.541
Statistical analysis
  • Acoramidis HCl 800 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: 7.10 · 96% CI 5.73 to 8.46
SecondaryAll-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD)

Number of deaths due to any cause was analyzed. Participants who had heart transplantation or implantation of a CMAD were handled in the same manner as death.

Time frame:
Baseline up to Month 30
Reported as:
Count of participants · Participants
All-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD)
ParticipantsAcoramidis HCl 800 mgPlacebo
All-cause Mortality by Month 30, Including Death Due to Any Cause, Heart Transplant or Cardiac Mechanical Assist Device (CMAD)7952
Statistical analysis
  • Acoramidis HCl 800 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0569 (Cochran-Mantel-Haenszel test is stratified by randomization stratification factors of genotype, NT-proBNP level and eGFR level as recorded in IXRS.) · Relative risk reduction (%): 25

Adverse events

Collected over In Study AG10-301 participants, treatment emergent adverse events (TEAEs) are defined as (a) events with onset after the first dose of study drug, or (b) if the event was present before the first dose of study drug, but increased in severity after the first dose of study drug, and (c) with onset date or severity increase date <= 30 days after the last dose of study drug (through AG10-301 Study completion, 30 months) or until the first dose in open label extension Study AG10-304.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acoramidis HCl 800 mg84/421 (20%)230/421 (54.6%)410/421 (97.4%)
Placebo55/211 (26.1%)137/211 (64.9%)199/211 (94.3%)
Most frequent serious events
Showing 10 of 313
Most frequent serious events
EventAcoramidis HCl 800 mgPlacebo
Cardiac failureCardiac disorders45/42139/211
Atrial fibrillationCardiac disorders19/42115/211
Cardiac failure acuteCardiac disorders21/42114/211
Acute kidney injuryRenal and urinary disorders21/4218/211
COVID-19 pneumoniaInfections and infestations2/4218/211
FallInjury, poisoning and procedural complications13/4212/211
PneumoniaInfections and infestations12/4216/211
BradycardiaCardiac disorders11/4212/211
Ventricular tachycardiaCardiac disorders6/4215/211
HypervolaemiaMetabolism and nutrition disorders3/4215/211
Most frequent other events
Showing 10 of 41
Most frequent other events
EventAcoramidis HCl 800 mgPlacebo
Cardiac failureCardiac disorders69/42161/211
COVID-19Infections and infestations80/42127/211
FallInjury, poisoning and procedural complications59/42138/211
DyspnoeaRespiratory, thoracic and mediastinal disorders51/42137/211
Atrial fibrillationCardiac disorders55/42136/211
ConstipationGastrointestinal disorders51/42131/211
Urinary tract infectionInfections and infestations46/42126/211
FatigueGeneral disorders42/42126/211
Oedema peripheralGeneral disorders33/42125/211
DiarrhoeaGastrointestinal disorders48/42116/211

Baseline characteristics

Safety Population

Age, Categorical
Age, Categorical(Participants)Acoramidis HCl 800 mgPlaceboTotal
<=18 years000
Between 18 and 65 years12921
>=65 years409202611
Age, Continuous
Age, Continuous(years)Acoramidis HCl 800 mgPlaceboTotal
Mean77.37 ± 6.45077.09 ± 6.76377.27 ± 6.552
Sex: Female, Male
Sex: Female, Male(Participants)Acoramidis HCl 800 mgPlaceboTotal
Female372562
Male384186570
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acoramidis HCl 800 mgPlaceboTotal
Hispanic or Latino8412
Not Hispanic or Latino401199600
Unknown or Not Reported12820
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Acoramidis HCl 800 mgPlaceboTotal
American Indian or Alaska Native011
Asian10313
Native Hawaiian or Other Pacific Islander011
Black or African American201030
White368187555
More than one race202
Unknown or Not Reported21930
Distance Walked During the 6 Minute Walk Test (6MWT)
Distance Walked During the 6 Minute Walk Test (6MWT)(Meter)Acoramidis HCl 800 mgPlaceboTotal
Mean361.21 ± 103.705348.37 ± 93.564356.91 ± 100.531
Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)(units on a scale)Acoramidis HCl 800 mgPlaceboTotal
Mean71.52 ± 19.38770.31 ± 20.54171.12 ± 19.773
Serum TTR (Prealbumin) Level
Serum TTR (Prealbumin) Level(mg/dL)Acoramidis HCl 800 mgPlaceboTotal
Mean23.16 ± 5.64323.63 ± 6.07023.32 ± 5.788
09

Study locations

104 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Pacific Heart Institute
    Santa Monica, California 90404, United States
  • University of Colorado Hospital - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Yale School of Medicine
    New Haven, Connecticut 06473, United States
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • University of Miami - Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Piedmont Heart Institute Athens
    Athens, Georgia 30606, United States
  • Emory Heart and Vascular Center
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • NorthShore University Health System
    Evanston, Illinois 60201, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • MedStar Medical Group Cardiology at Franklin Square Medical Center
    Baltimore, Maryland 21218, United States
  • Boston University School of Medicine
    Boston, Massachusetts 02118, United States
  • Saint Elizabeth's Medical Center
    Boston, Massachusetts 02135, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Saint Luke's Hospital - Kansas City
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • New York University Langone Health
    New York, New York 10010, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10034, United States
  • Laurelton Heart Specialist
    Rosedale, New York 11422, United States
  • University of North Carolina - Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • The Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Prisma Health - Greenville Memorial Hospital
    Greenville, South Carolina 29605, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298, United States
  • Carilion Clinic Roanoke Heart Institute
    Roanoke, Virginia 24014, United States
  • University of Washington School of Medicine
    Seattle, Washington 98195, United States
  • Providence Sacred Heart Medical Center
    Spokane, Washington 99204, United States
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Box Hill Hospital
    Box Hill, Australia
  • Royal Hobart Hospital
    Hobart, Australia
  • Fiona Stanley Hospital
    Murdoch, Australia
  • Saint Vincent's Hospital Sydney
    Sydney, 2010, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Australia
  • Ziekenhuis Oost-Limburg - Campus Sint-Jan
    Genk, Limburg, Belgium
  • Jessa Ziekenhuis - Campus Virga Jesse
    Hasselt, Limburg, Belgium
  • Algemeen Ziekenhuis Sint-Jan Brugge-Oostende
    Brugge, West Vlaanderen, Belgium
  • Onze-Lieve-Vrouw Ziekenhuis Aalst
    Aalst, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, Belgium
  • Hospital Cárdio Pulmonar
    Salvador, Bahia, Brazil
  • Santa Casa de Misericordia - Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90020-090, Brazil
  • CAPED - Centro Avançado de Pesquisa e Estudos para o Diagnóstico
    Ribeirão Preto, Sao Paulo 14026-900, Brazil
  • INCOR
    São Paulo, Sao Paulo, Brazil
  • Instituto de Cardiologia do Rio Grande do Sul
    Porto Alegre, Brazil
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • University of British Columbia
    Vancouver, British Columbia V5Z 1M9, Canada
  • CancerCare Manitoba - St. Boniface
    Winnipeg, Manitoba, Canada
  • Halifax Infirmary
    Halifax, Nova Scotia B3H 3A7, Canada
  • Toronto Heart Centre
    Toronto, Ontario M4P 1E4, Canada
  • University of Toronto
    Toronto, Ontario M5G 2N2, Canada
  • Centre Hospitalier de L'Universite de Montreal - Hôpital Notre-Dame
    Montréal, Quebec H2X 3H8, Canada
  • Hôpital du Sacré-Coeur de Montréal
    Montréal, Quebec H4J 1C5, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec
    Quebec City, Quebec G1V 4G5, Canada
  • Hôpital régional de Rimouski
    Rimouski, Quebec G5L 5T1, Canada
  • Montreal Heart Institute
    Montréal, Canada
  • St. Anne´s University Hospital
    Brno Střed, Czechia
  • General University Hospital in Prague
    Nové Město, Czechia
  • Institute for Clinical and Experimental Medicine
    Prague, Czechia
  • Aarhus Universitetshospital
    Aarhus, Dinamarca 8200, Denmark
  • Alexandra General Hospital of Athens
    Athens, Attica, Greece
  • Mater Misericordiae University Hospital
    Dublin, Ireland
  • Saint Vincents University Hospital
    Dublin, Ireland
  • Hadassah University Hospital Ein Kerem
    Jerusalem, Israel
  • The Chaim Sheba Medical Center
    Tel Hashomer, Israel
  • Ospedale San Donato
    Arezzo, Italy
  • Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi
    Bologna, Italy
  • Azienda Ospedaliero - Universitaria Careggi
    Firenze, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanità Pubblica
    Pisa, Italy
  • Ospedale degli Infermi
    Rimini, Italy
  • Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma
    Roma, Italy
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-Do 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Gyeonggi-Do 13620, Korea, Republic of
  • Maastricht Universitair Medisch Centrum
    Maastricht, Limburg 6229 HX, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, Netherlands
  • Middlemore Hospital
    Otahuhu, Auckland 1640, New Zealand
  • Waikato Hospital
    Hamilton, Waikato 3240, New Zealand
  • National Institute of Cardiology
    Warsaw, Poland
  • Centro Hospitalar de Lisboa Norte EPE- Hospital Santa Maria
    Lisboa, Portugal
  • Centro Hospitalar do Porto
    Porto, 4099-001, Portugal
  • Clínica Universidad de Navarra
    Pamplona, Navarra, Spain
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, Spain
  • Hospital Juan Ramón Jiménez
    Huelva, 21005, Spain
  • Hospital Juan Ramón Jiménez
    Huelva, Spain
  • Clinica Universidad de Navarra Madrid
    Madrid, Spain
  • Hospital Universitario Puerta de Hierro
    Madrid, Spain
  • Hospital Son Llàtzer
    Palma De Mallorca, Spain

Showing the first 100 of 104 sites across 18 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Stern LK, Kittleson MM. Updates in Cardiac Amyloidosis Diagnosis and Treatment. Curr Oncol Rep. 2021 Mar 16;23(4):47. doi: 10.1007/s11912-021-01028-8. PubMed 33725199 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in May 2023, 49 months.

Results were first posted in Jun 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2019
First posted
Mar 4, 2019
StartActual
Mar 19, 2019
Primary completionActual
May 11, 2023
CompletionActual
May 11, 2023
Results first posted
Jun 27, 2024
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03860935
Responsible party
Sponsor
First posted
Mar 4, 2019
Start date
Mar 19, 2019
Primary completion
May 11, 2023
Completion
May 11, 2023
Results posted
Jun 27, 2024
Last update
Jun 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acoramidis

Start the discussion